Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A short BRCA2-derived cell-penetrating peptide targets RAD51 function and confers hypersensitivity towards PARP inhibition.

Trenner A, Godau J, Sartori AA.

Mol Cancer Ther. 2018 Apr 13. pii: molcanther.1156.2017. doi: 10.1158/1535-7163.MCT-17-1156. [Epub ahead of print]

PMID:
29654063
2.

Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus.

Roeben B, Maetzler W, Vanmechelen E, Schulte C, Heinzel S, Stellos K, Godau J, Huber H, Brockmann K, Wurster I, Gaenslen A, Grüner E, Niebler R, Eschweiler GW, Berg D; TREND study team.

J Alzheimers Dis. 2016 Mar 16;52(1):161-9. doi: 10.3233/JAD-150575.

PMID:
27003209
3.

Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease.

Herfurth M, Godau J, Kattner B, Rombach S, Grau S, Maetzler W, Berg D.

Parkinsonism Relat Disord. 2015 Apr;21(4):413-6. doi: 10.1016/j.parkreldis.2015.01.016. Epub 2015 Feb 7.

PMID:
25701468
4.

Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.

Liepelt-Scarfone I, Lerche S, Behnke S, Godau J, Gaenslen A, Pausch C, Fassbender K, Brockmann K, Srulijes K, Huber H, Wurster I, Berg D.

J Neurol. 2015 Feb;262(2):451-8. doi: 10.1007/s00415-014-7584-4. Epub 2014 Dec 2.

PMID:
25451854
5.

Does prone positioning increase intracranial pressure? A retrospective analysis of patients with acute brain injury and acute respiratory failure.

Roth C, Ferbert A, Deinsberger W, Kleffmann J, Kästner S, Godau J, Schüler M, Tryba M, Gehling M.

Neurocrit Care. 2014 Oct;21(2):186-91. doi: 10.1007/s12028-014-0004-x.

PMID:
24985500
6.

Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.

Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, Cirovic B, Leutz A, Manz R, Bogen B, Dörken B, Jundt F.

Blood Cancer J. 2014 Jun 13;4:e217. doi: 10.1038/bcj.2014.37.

7.

Hand function is impaired in healthy older adults at risk of Parkinson's disease.

Todd G, Haberfield M, Faulkner PL, Rae C, Hayes M, Wilcox RA, Taylor JL, Gandevia SC, Godau J, Berg D, Piguet O, Double KL.

J Neural Transm (Vienna). 2014 Nov;121(11):1377-86. doi: 10.1007/s00702-014-1218-y. Epub 2014 May 3.

PMID:
24793059
8.

Prodromal features for Parkinson's disease--baseline data from the TREND study.

Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D.

Eur J Neurol. 2014 May;21(5):766-72. doi: 10.1111/ene.12382. Epub 2014 Feb 24.

PMID:
24612314
9.

Risk factors and prodromal markers and the development of Parkinson's disease.

Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg D.

J Neurol. 2014 Jan;261(1):180-7. doi: 10.1007/s00415-013-7171-0. Epub 2013 Nov 5.

PMID:
24190794
10.

Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach.

Liepelt-Scarfone I, Gräber S, Fruhmann Berger M, Feseker A, Baysal G, Csoti I, Godau J, Gaenslen A, Huber H, Srulijes K, Brockmann K, Berg D.

Int J Alzheimers Dis. 2012;2012:910757. doi: 10.1155/2012/910757. Epub 2012 Oct 18.

11.

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.

Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W.

Mov Disord. 2013 Feb;28(2):216-9. doi: 10.1002/mds.25192. Epub 2012 Oct 31.

PMID:
23115051
12.

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W; PRIPS study group.

Eur J Neurol. 2013 Jan;20(1):102-8. doi: 10.1111/j.1468-1331.2012.03798.x. Epub 2012 Aug 1.

PMID:
22852790
13.

Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression.

Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D.

J Alzheimers Dis. 2012;32(1):95-100.

PMID:
22766733
14.

Characterizing POLG ataxia: clinics, electrophysiology and imaging.

Synofzik M, Srulijes K, Godau J, Berg D, Schöls L.

Cerebellum. 2012 Dec;11(4):1002-11. doi: 10.1007/s12311-012-0378-2.

PMID:
22528963
15.

Neuroimaging: current role in detecting pre-motor Parkinson's disease.

Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K.

Mov Disord. 2012 Apr 15;27(5):634-43. doi: 10.1002/mds.24976. Review.

PMID:
22508281
16.

Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study.

Hobert MA, Niebler R, Meyer SI, Brockmann K, Becker C, Huber H, Gaenslen A, Godau J, Eschweiler GW, Berg D, Maetzler W.

PLoS One. 2011;6(11):e27831. doi: 10.1371/journal.pone.0027831. Epub 2011 Nov 16.

17.

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W.

Arch Neurol. 2011 Jul;68(7):932-7. doi: 10.1001/archneurol.2011.141.

PMID:
21747034
18.

Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease.

Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, Berg D.

Arch Neurol. 2011 Jul;68(7):925-31. doi: 10.1001/archneurol.2011.129.

PMID:
21747033
19.

Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease.

Liepelt-Scarfone I, Graeber S, Feseker A, Baysal G, Godau J, Gaenslen A, Maetzler W, Berg D.

Parkinsons Dis. 2011;2011:540843. doi: 10.4061/2011/540843. Epub 2011 May 23.

20.

Transcranial sonography reveals cerebellar, nigral, and forebrain abnormalities in Friedreich's ataxia.

Synofzik M, Godau J, Lindig T, Schöls L, Berg D.

Neurodegener Dis. 2011;8(6):470-5. doi: 10.1159/000327751. Epub 2011 Jun 9.

PMID:
21659723
21.

The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients.

Fritz B, Rombach S, Godau J, Berg D, Horstmann T, Grau S.

Gait Posture. 2011 Jun;34(2):234-8. doi: 10.1016/j.gaitpost.2011.05.004. Epub 2011 Jun 2.

PMID:
21640591
22.

Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.

Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M.

J Alzheimers Dis. 2011;26(1):171-9. doi: 10.3233/JAD-2011-110221.

PMID:
21593566
23.

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B.

Mov Disord. 2011 Jun;26(7):1243-50. doi: 10.1002/mds.23616. Epub 2011 Apr 11.

PMID:
21484867
24.

Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.

Gröger A, Chadzynski G, Godau J, Berg D, Klose U.

Eur Radiol. 2011 Sep;21(9):1962-9. doi: 10.1007/s00330-011-2123-5. Epub 2011 Apr 12.

PMID:
21484351
25.

The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease.

Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D.

Mov Disord. 2011 Mar;26(4):653-8. doi: 10.1002/mds.23499. Epub 2011 Mar 2.

26.

Relation of risk factors and putative premotor markers for Parkinson's disease.

Liepelt-Scarfone I, Behnke S, Godau J, Schweitzer KJ, Wolf B, Gaenslen A, Berg D.

J Neural Transm (Vienna). 2011 Apr;118(4):579-85. doi: 10.1007/s00702-010-0553-x. Epub 2011 Jan 6.

PMID:
21210286
27.

Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases.

Godau J, Berg D.

Sleep Disord. 2011;2011:468952. doi: 10.1155/2011/468952. Epub 2011 Jan 23.

28.

Microglia activation is related to substantia nigra echogenicity.

Berg D, Godau J, Riederer P, Gerlach M, Arzberger T.

J Neural Transm (Vienna). 2010 Nov;117(11):1287-92. doi: 10.1007/s00702-010-0504-6. Epub 2010 Nov 6.

PMID:
21057966
29.

Poor effect of guideline based treatment of restless legs syndrome in clinical practice.

Godau J, Spinnler N, Wevers AK, Trenkwalder C, Berg D.

J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1390-5. doi: 10.1136/jnnp.2010.211417. Epub 2010 Sep 30.

PMID:
20884674
30.

Restless legs and substantia nigra hypoechogenicity are common features in Friedreich's ataxia.

Synofzik M, Godau J, Lindig T, Schöls L, Berg D.

Cerebellum. 2011 Mar;10(1):9-13. doi: 10.1007/s12311-010-0215-4.

PMID:
20865356
31.

Transcranial sonography in restless legs syndrome.

Godau J, Sojer M.

Int Rev Neurobiol. 2010;90:199-215. doi: 10.1016/S0074-7742(10)90015-9. Review.

PMID:
20692504
32.

Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly.

Berg D, Seppi K, Liepelt I, Schweitzer K, Wollenweber F, Wolf B, Dillmann U, Stockner H, Godau J, Kiechl S, Gaenslen A, Willeit J, Di Santo A, Maetzler W, Gasser T, Poewe W, Behnke S.

Mov Disord. 2010 Jul 30;25(10):1464-9. doi: 10.1002/mds.23114.

PMID:
20629151
33.

Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease.

Godau J, Herfurth M, Kattner B, Gasser T, Berg D.

J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8. doi: 10.1136/jnnp.2009.175752. Epub 2010 Feb 22.

PMID:
20176597
34.

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.

Liepelt I, Gaenslen A, Godau J, Di Santo A, Schweitzer KJ, Gasser T, Berg D.

Alzheimers Dement. 2010 Jan;6(1):70-4. doi: 10.1016/j.jalz.2009.04.1231.

PMID:
20129321
35.

Role of transcranial ultrasound in the diagnosis of movement disorders.

Godau J, Berg D.

Neuroimaging Clin N Am. 2010 Feb;20(1):87-101. doi: 10.1016/j.nic.2009.08.003. Review.

PMID:
19959021
36.

Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population.

Liepelt I, Behnke S, Schweitzer K, Wolf B, Godau J, Wollenweber F, Dillmann U, Gaenslen A, Di Santo A, Maetzler W, Berg D.

Neurobiol Aging. 2011 Sep;32(9):1599-606. doi: 10.1016/j.neurobiolaging.2009.10.004. Epub 2009 Nov 7.

PMID:
19897277
37.

The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri.

Mänz C, Godau J, Berg D, Bender B, Ernemann U, Klose U.

Neuroradiology. 2010 Aug;52(8):745-50. doi: 10.1007/s00234-009-0612-x. Epub 2009 Oct 27.

PMID:
19859701
38.

Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, Herbst H, Berg D.

Mov Disord. 2009 Jul 30;24(10):1504-11. doi: 10.1002/mds.22662.

PMID:
19489069
39.

Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome.

Godau J, Manz A, Wevers AK, Gaenslen A, Berg D.

Mov Disord. 2009 Jan 15;24(1):133-7. doi: 10.1002/mds.22391.

PMID:
19170194
40.

Transcranial sonography in movement disorders.

Berg D, Godau J, Walter U.

Lancet Neurol. 2008 Nov;7(11):1044-55. doi: 10.1016/S1474-4422(08)70239-4. Review.

PMID:
18940694
41.

Multiregional brain iron deficiency in restless legs syndrome.

Godau J, Klose U, Di Santo A, Schweitzer K, Berg D.

Mov Disord. 2008 Jun 15;23(8):1184-7. doi: 10.1002/mds.22070.

PMID:
18442125
42.

The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study.

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D.

Lancet Neurol. 2008 May;7(5):417-24. doi: 10.1016/S1474-4422(08)70067-X. Epub 2008 Apr 3.

PMID:
18394965
43.

Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population.

Liepelt I, Wendt A, Schweitzer KJ, Wolf B, Godau J, Gaenslen A, Bruessel T, Berg D.

J Neural Transm (Vienna). 2008 Jul;115(7):993-9. doi: 10.1007/s00702-008-0043-6. Epub 2008 Mar 27.

PMID:
18368284
44.

Sonographic abnormalities of brainstem structures in restless legs syndrome.

Godau J, Wevers AK, Gaenslen A, Di Santo A, Liepelt I, Gasser T, Berg D.

Sleep Med. 2008 Oct;9(7):782-9. Epub 2007 Nov 19.

PMID:
18024170
45.

Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Müller A, Gasser T, Berg D.

J Neural Transm (Vienna). 2007 Sep;114(9):1167-71. Epub 2007 Apr 20.

PMID:
17446999
46.

Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome.

Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D.

Mov Disord. 2007 Jan 15;22(2):187-92.

PMID:
17133515
47.

C5a initiates the inflammatory cascade in immune complex peritonitis.

Godau J, Heller T, Hawlisch H, Trappe M, Howells E, Best J, Zwirner J, Verbeek JS, Hogarth PM, Gerard C, Van Rooijen N, Klos A, Gessner JE, Köhl J.

J Immunol. 2004 Sep 1;173(5):3437-45.

Supplemental Content

Support Center